A Phase 2/3 interventional study of Exparel and Bupivacain in Back Pain, Surgery-Complications and Narcotic Use, sponsored by Foundation for Orthopaedic Research and Education. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Foundation for Orthopaedic Research and Education · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.
Among the 307 studies in Back Pain with a site in United States, this one is the 131st largest by planned enrollment of the 262 interventional ones that give a count, is one of 19 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 21 of the 50 other live ones, and was the 274th registered.
729 studies on the registry are indexed under Back Pain; 110 are open to participants now.
Browse Back Pain studies →38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
University of Houston · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Northwestern University · Sites in United States, Thailand, Ukraine
University of Colorado, Denver · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 21–84
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 33 · Phase 4 30
First in 1997; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is close to the median of 70 across 594 interventional studies indexed under Back Pain.
Median enrollment 76 across the 262 interventional studies, 133 across the 44 observational. Of the 228 that completed or were terminated, 105 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 307 have an industry lead sponsor. The 10 most frequent:
Foundation for Orthopaedic Research and Education is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Foundation for Orthopaedic Research and Education has 1 study filed under Back Pain — fewer than ten, so there is no comparison to draw.
21 of the studies in Back Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT05052541Phase 3University of Colorado, DenverSafety and Efficacy of Oral Cannabis in Chronic Spine Pain | 2027-06 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 307 studies in Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine. A total of 30 mL of mixed solution is injected into the thoracolumbar interfacial plane.
Drug: Exparel
Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection. Subjects will receive 30 mL of the solution, injected into the thoracolumbar interfacial plane.
Drug: Bupivacain
20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine
Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
Compare efficacy of thoracolumbar interfacial plane block with Exparel vs. standard of care (0.25% Bupivacaine HCL) is surgical subjects undergoing 1-3 level elective transforaminal lumbar interbody fusion.
Data will be analyzed by randomized treatment group to determine efficacy. Superiority of treatment with EXPAREL compared with Bupivacaine hydrochloride will be determined using linear regression adjusting for Pain Catastrophizing Scale with treatment as main effect for the primary efficacy endpoint of area under the curve of the Numerical rating scale pain intensity scores from 0 to 72 hours post-surgery.
Time frame: 0-72 hours post-operatively
Total Postsurgical opioid consumption
The following data points will be recorded to further claim the investigators hypothesis of treatment with EXPAREL compared to Bupivacaine hydrochloride. • Total postsurgical opioid consumption in oral morphine equivalents (Oral morphine equivalents) from 0 to 76 hours post-surgery
Time frame: 0-72 hours postoperatively
Time to discharge
collect hours of hospital stay
Time frame: 0-72 hours postoperatively
Time to ambulation
collect time ambulated from surgery
Time frame: 0-72 hours postoperatively
Maximum ambulated distance
Physical Therapy will document the distance subject could ambulate after surgery
Time frame: 0-72 hours postoperatively
Numeric Rating Pain Scale (Physical Therapy)
Measure pain score (scale of 0-10 with 0 indicates no pain and 10 severe pain) during physical therapy (ambulation)
Time frame: 0-72 hours postoperatively
Numeric Rating Pain Scale
Numerical rating scale pain intensity scores at 24hour, 36hour, 60hour, and 72hour from the end of surgery and again at the first clinic visit postoperatively (scale of 0-10 with 0 indicates no pain and 10 severe pain)
Time frame: 0-72 hours with additional follow-up at 14 days (first clinic visit)
Oswestry Disability Index (ODI)
10 questions relating to function specific to low back pain given before surgery and collected at 14 day post op visit.
Time frame: 0- 14 days postoperatively
Pain Catastrophizing Scale (PCS)
This scale measures thoughts and feelings that may be associated with pain. it is rated 0-5 with 0 indicating not at all, 1 indicating to a slight degree, 2 indicates a moderate degree, 3 indicates a great degree and 4 idicates all the time. There are 13 statements that are rated, the ratings are scored to determine where each subject falls in the scale.
Time frame: 0-14 days postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine
Foundation for Orthopaedic Research and Education